- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
NICE allows extra time for agreement on ataluren price
4 May 2016 • Author: Victoria White, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has allowed extra time for further discussions on access arrangements for PTC Therapeutics’ Translarna (ataluren) for Duchenne Muscular Dystrophy caused by nonsense mutation before its final guidance is published.
NHS England and PTC Therapeutics have been asked to reach agreement on the cost of the drug to the NHS within 8 weeks. This additional time will run from the end of the appeal period, which has been extended by a further week to 11 May.
Last month, NICE issued draft guidance recommending ataluren for eligible children under certain circumstances.
One of those was that a confidential agreement on the overall cost of ataluren be reached between NHS England and PTC Therapeutics. Because agreement has not been reached NICE has allowed further time to enable agreement to be reached and the medicine made available.
Commenting on the announcement, Sir Andrew Dillon, chief executive of NICE, said: “The NICE committee was clear that ataluren has the potential to offer benefits to children with this cruel disease and their families and considered that it should be made available. However because of its high cost, a financial agreement must be reached between NHS England and the company.
“We have granted this extra time in order for that to happen. It provides an opportunity for NHS England and the company to act quickly to resolve any outstanding issues on price so the guidance can be published.”
If agreement is reached within the 8 week extension, NICE will publish final guidance and the standard 90 day funding directive will be applicable.
If no agreement has been reached in that time, NICE will advise the Department of Health that it is unable to publish the guidance.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics